RedHill's Antibiotic Approach For Crohn's Shows Promise, Caveats Remain

Top-line data for a Phase III trial of RedHill's antibiotic combination for use in Crohn's disease show the study has hit its primary endpoint, but there is still some way to go before filings can be made for the novel approach.

SC1808_Treasure Map_516275821_1200.jpg — Has RedHill Found The Map to Crohn's Sales Treasure?

RedHill Biopharma Ltd.'s investigational antibiotic therapy for Crohn's disease patients, RHB-104, has met its primary endpoint and key secondary endpoints in its Phase III MAP US study, but the product has more to prove before the company is likely to make a successful filing.

The oral combination therapy contains rifabutin, clarithromycin and clofazimine, and is being developed as a potential treatment for Mycobacterium avium...